SECURITIES AND EXCHANGE COMMISSION
UNDER
THE SECURITIES ACT OF 1933
|
Delaware
|
| |
27-3269467
|
|
|
(State or other jurisdiction
of incorporation or organization) |
| |
(I.R.S. Employer
Identification No.) |
|
Needham, Massachusetts 02494
(781) 292-4200
Chief Executive Officer
Verastem, Inc.
117 Kendrick Street, Suite 500
Needham, Massachusetts 02494
(781) 292-4200
Thomas Danielski
Ropes & Gray LLP
Prudential Tower
800 Boylston St.
Boston, Massachusetts 02199
(617) 951-7000
(Approximate date of commencement of proposed sale to the public)
|
Large accelerated filer
☐
|
| |
Accelerated filer
☐
|
|
|
Non-accelerated filer
☒
|
| |
Smaller reporting company
☒
|
|
| | | |
Emerging growth company
☐
|
|
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 10 | | | |
| | | | | 13 | | | |
| EXPERTS | | | | | 13 | | |
| | | | | 13 | | | |
| | | | | 13 | | |
Name and Address
|
| |
Number of
Shares of Common Stock Beneficially Owned Prior to Offering |
| |
Percentage of
Shares of Common Stock Beneficially Owned Prior to Offering |
| |
Number of
Shares of Common Stock Offered |
| |
Number of
Shares of Common Stock Beneficially Owned After Offering |
| |
Percentage of
Shares of Common Stock Beneficially Owned After Offering |
| |||||||||||||||
Entities affiliated with Oberland Capital Management LLC(1)
|
| | | | 1,416,939(1) | | | | | | 2.75% | | | | | | 1,416,939 | | | | | | — | | | | | | — | | |
117 Kendrick Street, Suite 500
Needham, Massachusetts 02494
(781) 292-4279
email address: [email protected]
|
SEC registration fee
|
| | | $ | 1,486 | | |
|
Legal fees and expenses
|
| | | $ | 250,000 | | |
|
Accounting fees and expenses
|
| | | $ | 30,000 | | |
|
Miscellaneous fees and expenses
|
| | | $ | 10,000 | | |
|
Total
|
| | | $ | 291,486 | | |
|
Exhibit
Number |
| |
Description of Document
|
|
| 4.2 | | | | |
| 4.3 | | | Stock Purchase Agreement, dated January 13, 2025, by and among Verastem, Inc. and each purchaser party thereto (incorporated by reference to Exhibit 10.2 to the form 8-K filed by the Registrant with the Securities and Exchange Commission on January 13, 2025) | |
| 4.4 | | | | |
| 4.5 | | | | |
| 5.1 | | | | |
| 23.1 | | | | |
| 23.2 | | | | |
| 24.1 | | | | |
| 107 | | | |
Chief Executive Officer
(Principal executive officer)
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ Daniel W. Paterson
Daniel W. Paterson
|
| | Chief Executive Officer and Director (Principal executive officer) | | |
March 20, 2025
|
|
|
/s/ Daniel Calkins
Daniel Calkins
|
| |
Chief Financial Officer
(Principal financial and accounting officer) |
| |
March 20, 2025
|
|
|
/s/ Michael Kauffman, MD, PH.D.
Michael Kauffman, MD, PH.D.
|
| | Director | | |
March 20, 2025
|
|
|
/s/ Paul Bunn, MD
Paul Bunn, MD
|
| | Director | | |
March 20, 2025
|
|
|
/s/ Rob Gagnon
Rob Gagnon
|
| | Director | | |
March 20, 2025
|
|
|
/s/ Anil Kapur
Anil Kapur
|
| | Director | | |
March 20, 2025
|
|
|
/s/ John Johnson
John Johnson
|
| | Director | | |
March 20, 2025
|
|
|
/s/ Michelle Robertson
Michelle Robertson
|
| | Director | | |
March 20, 2025
|
|
|
/s/ Eric Rowinsky, MD
Eric Rowinsky, MD
|
| | Director | | |
March 20, 2025
|
|
|
/s/ Brian Stuglik
Brian Stuglik
|
| | Director | | |
March 20, 2025
|
|
|
/s/ Karin Tollefson
Karin Tollefson
|
| | Director | | |
March 20, 2025
|
|